Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Lymphoma
Interventions
DRUG

Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)

"rituximab 375 mg/m2 IV Weekly x 4 1 cycle only~dexamethasone 40 mg PO/IV Days 2-5 q 21 days 2 cycles~oxaliplatin 130 mg/m2 IV Day 2 q 21 days 2 cycles~cytosine arabinoside 2000 mg/m2 x 2 doses IV Days 2-3 q 21 days 2 cycles~pegfilgrastim 6 mg SQ Day 4 q21 days 2 cycles"

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mayo Clinic

OTHER

lead

Academic and Community Cancer Research United

OTHER

NCT00166439 - Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma | Biotech Hunter | Biotech Hunter